Autopsy report · NCT00288522
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 3 months before it stopped.
- 5 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Ipsen
- Sponsor type
- Industry
- Conditions
- Thyroid-Associated Ophthalmopathy
- Interventions
- Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
- Participants
- 5
- Sites
- 1
- Countries
- Spain
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.